Liraglutide

Catalog No.S8256 Batch:S825604

Print

Technical Data

Formula

C172H265N43O51
Molecular Weight 3751.25 CAS No. 204656-20-2
Solubility (25°C)* In vitro Water 100 mg/mL (26.65 mM)
 
 
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
5.0mg/ml Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist.
Targets
GLP-1 receptor [1]
In vitro

Liraglutide attenuates induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression in human vascular endothelial cells (hVECs) in vitro and may afford protection against endothelial cell dysfunction (ECD), an early abnormality in diabetic vascular disease. In vitro studies demonstrates GLP-1R-dependent liraglutide-mediated inhibition of stimulated PAI-1 and VAM expression[3].
In vivo

In vivo studies of vascular reactivity and immunohistochemical analysis are performed in the ApoE-/- mouse model. They demonstrate significant improvement in endothelial function in liraglutide treated mice, a GLP-1R dependent effect. Liraglutide treatment also increases endothelial nitric oxide synthase (eNOS) and reduces intercellular adhesion molecule-1 (ICAM-1) expression in aortic endothelium, an effect again dependent on the GLP-1R[3]. Liraglutide reduces hyperglycemia in T2D mouse models by increasing pancreatic b cell mass through enhanced proliferation[2].

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    human umbilical vein endothelial cell line C11-STH20

  • Concentrations

    100 nM

  • Incubation Time

    16 h

  • Method

    C11-STH cells are cultured to confluence at 37°C in gelatin-coated Nunclon cell culture dishes in Media-199 supplemented with penicillin/streptomycin, 20% FCS, 20 µg/ml endothelial cell growth factor and 20 µg/ml heparin. C11-STH cells are incubated under serum free conditions with liraglutide (100 nM) or the GLP-1 receptor antagonist exendin (9-39) (100 nM) alone or with 10 ng/ml TNFα for 16 h alone or in combination with liraglutide and/or exendin (9-39). ELISA assays for VCAM-1 and ICAM-1 are performed using conditioned medium from C11-STH cells to determine protein expression levels.
Animal Study:

[2]
  • Animal Models

    Athymic nude mice

  • Dosages

    300 μg/kg/day

  • Administration

    s.c.

Selleck's Liraglutide has been cited by 24 publications

An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy [ J Immunother Cancer, 2024, 12(3)e008431] PubMed: 38458640
GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation [ J Transl Med, 2024, 22(1):954] PubMed: 39434134
Hypertonicity during a rapid rise in D-glucose mediates first-phase insulin secretion [ Front Endocrinol (Lausanne), 2024, 15:1395028] PubMed: 38989001
Targeting Clic1 for the treatment of obesity: A novel therapeutic strategy to reduce food intake and body weight [ Mol Metab, 2023, 76:101794] PubMed: 37604246
Targeting Clic1 for the treatment of obesity: A novel therapeutic strategy to reduce food intake and body weight [ Mol Metab, 2023, 76:101794] PubMed: 37604246
A versatile pumpless multi-channel fluidics system for maintenance and real-time functional assessment of tissue and cells [ Cell Rep Methods, 2023, 3(11):100642] PubMed: 37963464
Molecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety [ bioRxiv, 2023, 10.1101/2023.10.31.564990] PubMed: 37961449
Dietary resistant starch ameliorating lipopolysaccharide-induced inflammation in meat ducks associated with the alteration in gut microbiome and glucagon-like peptide 1 signaling [ J Anim Sci Biotechnol, 2022, 13(1):91] PubMed: 35836245
Liraglutide, a glucagon-like peptide-1 receptor agonist, induces ADAM10-dependent ectodomain shedding of RAGE via AMPK activation in human aortic endothelial cells [ Life Sci, 2022, 292:120331] PubMed: 35041837
Improved Split TEV GPCR β-arrestin-2 Recruitment Assays via Systematic Analysis of Signal Peptide and β-arrestin Binding Motif Variants [ Biosensors (Basel), 2022, 13(1)48] PubMed: 36671883

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.